From: Exosomes in gastric cancer: roles, mechanisms, and applications
Cargo type | Exosomal cargo | Biofluids | Extraction method | Identification method | Method | Clinical value in GC | Reference |
---|---|---|---|---|---|---|---|
Protein | BARHL2 | Gastric juice | Commercial kit | Not shown | qRT-PCR | BARHL2 methylation yielded an AUC of 0.923 with 90% sensitivity and 100% specificity | [69] |
GKN1 | Serum | Commercial kit | TEM | ELISA | Discriminate GC patients from healthy individuals (AUC = 1.00), patients with hepatocellular (AUC = 1.00) and colorectal carcinomas (AUC = 0.98) | [47] | |
TGF-β1 | Plasma | Differential centrifugation | Western blot, immuno-EM and NTA | ELISA | Associated with lymph node metastasis | [43] | |
TRIM3 | Serum | Commercial kit | TEM and NTA | ELISA, western blot | Downregulated in GC and may serve as a biomarker for GC diagnosis | [52] | |
miRNA | miR-423-5p | Serum | Commercial kit | TEM, NTA and western blot | qRT-PCR | Higher diagnostic efficiency than CEA and CA-199; indicator for poor prognosis | [54] |
miR-451 | Serum | Commercial kit | Not shown | qRT-PCR | indicate poor prognosis of GC patients | [58] | |
miR-217 | Plasma | Differential centrifugation | Not shown | qRT-PCR | Higher expression in GC patients | [71] | |
miR-23b | Plasma | Ultracentrifugation | TEM | miRNA microarray, qRT-PCR | Predicts the recurrence and prognosis of GC patients in each tumor stage | [74] | |
miR-19b-3p and miR-106a-5p | Serum | Commercial kit | TEM and western blot | qRT-PCR | Related to GC lymphatic metastasis and TNM stage; more accurate than AFP and CA19–9 for GC diagnosis | [70] | |
miR10b-5p, miR195-5p, miR20a-3p, and miR296-5p | Serum | Commercial kit | Not shown | miRNA microarray, qRT-PCR | Elevated expression in GC patients | [24] | |
miR-424-5p and miR-590-3p | Serum | Commercial kit | TEM, NTA and western blot | miRNA profiling,qRT-PCR | Effective biomarker for diagnosing the stage of GC progression | [72] | |
miR-21 and miR-1225-5p | Peritoneal lavage fluid | Differential centrifugation | Not shown | miRNA microarray, qRT-PCR | Biomarker for the prediction of peritoneal dissemination | [73] | |
lncRNA | lncUEGC1 | Plasma | Serial centrifugation and discontinuous iodixanol gradient | TEM, NTA and western blot | RNA sequencing, qPCR | Potential early GC biomarker with higher diagnostic accuracy than CEA | [66] |
HOTTIP | Serum | Ultracentrifugation | Not shown | qRT-PCR | Higher diagnostic capability than CEA, CA 19–9 and CA72–4; correlated with poor overall survival | [65] | |
ZFAS1 | Serum | Commercial kit | TEM, NTA and western blot | qRT-PCR | Higher levels in GC patients; associated with lymph node metastasis and TNM stage | [64] | |
LINC00152 | Plasma | Commercial kit | TEM | qRT-PCR | Higher levels in GC patients | [10] | |
circRNA | circ-KIAA1244 | Plasma | Commercial kit | Not shown | circRNA microarray, qRT-PCR | Potential diagnostic and prognostic biomarker for GC | [67] |